Spero Therapeutics, Inc.
NASDAQ:SPRO · NASDAQ Global Select
+$0.08 today
Vol 7.11M · Avg 0.78M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
14.5%
avg -539.8%
ROIC
-0.0%
avg -242.8%
ROA
12.4%
avg -58.5%
Analysis
ROE is currently the strongest return metric at 14.5% versus its period average of -539.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Esther Rajavelu | CEO, President, CFO, Chief Business Officer, Treasurer & Director | $1.65M | — | 47 | $986,851.00 | 1.70% |
Timothy Keutzer | Chief Operating Officer | $1.23M | — | 58 | $742,506.00 | 1.28% |
John Raymond | Senior Vice President of Finance & Business Operations | — | — | — | $75,000.00 | 0.13% |
Sheila Finan | Senior VP & Controller | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
11
$568,328.13
Net Sentiment
$568,328.13
Net selling
Most Active
Rajavelu Esther
5 transactions
1–10 of 11
Analysis
Insiders reported 0 buys worth $0.00 and 11 sells worth $568,328.13 over the last 12 months. That adds up to net selling of $568,328.13. Rajavelu Esther was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +278.4% | +18.5% (10yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +278.4% over three years. Forward estimates point to Revenue at +18.5% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Opus Genetics, Inc.
NASDAQ:IRD
$335.61M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$149.97M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$137.20M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$104.12M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.16M
Seer, Inc.
NASDAQ:SEER
$94.84M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$61.98M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.41M
Actuate Therapeutics Inc
NASDAQ:ACTU
$50.24M
VistaGen Therapeutics, Inc.
VTGN
$22.74M
Who manages SPRO?
Spero Therapeutics, Inc. (SPRO) lists 4 active executives. The top listed executive is John Raymond, Senior Vice President of Finance & Business Operations.
Are SPRO insiders buying or selling?
Recent insider activity shows net buying of $23.13M.
Explore More
Continue the stock analysis
Jump to another research area for this company.